Measures of mortality in prostatic cancer.

The use of different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data. We have used different measures of mortality in the same group of 438 patients presenting consecutively with histologically proven adenocarcinoma of the prostate, in order to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, C. M., Ritchie, A. W., Chisholm, G. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971272/
https://www.ncbi.nlm.nih.gov/pubmed/2328216
_version_ 1782134874579140608
author Goodman, C. M.
Ritchie, A. W.
Chisholm, G. D.
author_facet Goodman, C. M.
Ritchie, A. W.
Chisholm, G. D.
author_sort Goodman, C. M.
collection PubMed
description The use of different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data. We have used different measures of mortality in the same group of 438 patients presenting consecutively with histologically proven adenocarcinoma of the prostate, in order to assess the values and deficiencies of each method. The use of expected and relative survival is shown to be valuable in allowing indirect but objective assessment of disease specific mortality in prostatic cancer.
format Text
id pubmed-1971272
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19712722009-09-10 Measures of mortality in prostatic cancer. Goodman, C. M. Ritchie, A. W. Chisholm, G. D. Br J Cancer Research Article The use of different expressions of mortality in prostate cancer can lead to difficulty in comparing reported data. We have used different measures of mortality in the same group of 438 patients presenting consecutively with histologically proven adenocarcinoma of the prostate, in order to assess the values and deficiencies of each method. The use of expected and relative survival is shown to be valuable in allowing indirect but objective assessment of disease specific mortality in prostatic cancer. Nature Publishing Group 1990-03 /pmc/articles/PMC1971272/ /pubmed/2328216 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Goodman, C. M.
Ritchie, A. W.
Chisholm, G. D.
Measures of mortality in prostatic cancer.
title Measures of mortality in prostatic cancer.
title_full Measures of mortality in prostatic cancer.
title_fullStr Measures of mortality in prostatic cancer.
title_full_unstemmed Measures of mortality in prostatic cancer.
title_short Measures of mortality in prostatic cancer.
title_sort measures of mortality in prostatic cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971272/
https://www.ncbi.nlm.nih.gov/pubmed/2328216
work_keys_str_mv AT goodmancm measuresofmortalityinprostaticcancer
AT ritchieaw measuresofmortalityinprostaticcancer
AT chisholmgd measuresofmortalityinprostaticcancer

Ejemplares similares